PHENOM
5.5.2021 09:02:13 CEST | Business Wire | Press release
Phenom , the No. 1 provider of Talent Experience Management (TXM) solutions, has been recognized as a Strategic Leader in the 2021 Fosway 9-Grid™ for Talent Acquisition . Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to meet the needs of complex enterprise-scale customers. Additionally, these solutions achieve higher levels of customer impact and advocacy compared to alternatives in the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005153/en/
The Fosway Group 9-Grid™ report for Talent Acquisition indicates the relative position of solutions and providers in the European talent acquisition system space. Analyzing data from the pandemic-altered market, the 2021 report also indicates how well software solutions scaled and performed for customers during last year’s volatility.
The report identified several key market and solution trends, including:
- THE GREAT REBOARD: Companies that lost jobs last year are pivoting to better recruitment technology to prepare for strategic, efficient rehiring.
- CANDIDATE EXPERIENCE: Transparent communication and agile decision-making underlie positive candidate experiences for both hires and non-hires.
- ARTIFICIAL INTELLIGENCE: Enterprises must leverage AI and automation in the hiring process to remain competitive.
- DIVERSITY, EQUITY & INCLUSION : Employers are realizing that diversity, equity and inclusion commitments must be a centerpiece in their HR strategies.
- VIDEO EXPERIENCES : Live video’s role in hiring will last beyond the pandemic, as companies realize it will be an efficient, authentic way to find best-fit candidates.
- INTERVIEW SCHEDULING : Chatbot and AI reduce friction across the scheduling process, generating more meaningful interactions between candidates and recruiters.
- TALENT MARKETPLACE : The most effective solutions need to include gigs, reskilling and upskilling for mutual employer/employee growth.
- COLLABORATIVE HIRING : Increasing communication between recruiter and hiring manager workflows is encouraged through integrations with Microsoft Teams and Slack.
“Phenom’s focus on disrupting the candidate and hiring experiences, has resonated strongly with the market,” said David Wilson, CEO of Fosway. “Rapid growth in adoption in enterprise organisations, as well as expanded physical presence and multiple market acquisitions is further accelerating its success in Europe and globally. All of these warrant Phenom’s increased rating as a Strategic Leader for Talent Acquisition in 2021.”
In 2020, the Phenom platform was adopted by 25,000 recruiters, talent marketers and hiring managers — helping them hire over 2 million people and engage over 3 million employees.
The Phenom platform automates administrative tasks and personalizes experiences, generating more impactful moments throughout the talent journey. As a result, candidates find the right job faster; employees learn and evolve; recruiters discover best-fit talent with efficiency and scale; and managers make stronger data-driven decisions to build their future teams.
Kuehne+Nagel, a global logistics company and Phenom customer, continues to see new value in the Phenom platform every day.
“Through Phenom, we’ve been able to strengthen our centralized recruitment activities per hemisphere, build an external career site and adapt it to local markets, implement a CRM — and now level up our employee experience — to build the most sophisticated talent acquisition ecosystem there is to offer,” said Sandra Aasma, global HR systems expert at Kuehne+Nagel.
“As Phenom continues to expand across EMEA, we’re honored to be one of the first-ever Strategic Leaders in Fosway’s Talent Acquisition grid,” said Jeff Carey, senior vice president of international business at Phenom. “Our new position on the Fosway 9-grid™ signals that enterprises routinely pick Phenom — galvanized by our sophisticated AI-powered platform and steadfast commitment to customers. By constantly upgrading and launching new products, we always stay at the front of a rapidly evolving HR technology market.”
Over 100 companies across the EMEA market have adopted Phenom’s platform to upgrade their talent experiences. As demand for Talent Experience Management has spiked, Phenom recently acquired two Europe-based companies and opened an office in Munich to complement its European headquarters in Rotterdam. With over 100 employees based in countries including Germany, France, Ireland, the Netherlands, Switzerland, Italy, Spain and the United Kingdom, Phenom continues to solidify EMEA’s importance within the company’s ultimate growth strategy.
To learn more about Phenom’s Strategic Leader position, please visit their blog .
To see Fosway’s full analysis, check out their 2021 9-grid™ .
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalizes and automates the talent journey for candidates, recruiters, employees and management with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates and employees find the right job, recruiters identify and engage the right talent, and management optimizes HR strategy, process and spend. Phenom was ranked among the fastest-growing technology companies in the 2020 Deloitte Technology Fast 500, and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com . Connect with Phenom on LinkedIn , Twitter , Facebook , YouTube and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005153/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom